Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2003)
26 slides from Starpharma's shareholder meeting presentation, Nov 19, 2003
Slide 1: Chairman's Address, Annual General Meeting
@ starpharma Chairman’s Address Annual General Meeting of Starpharma Pooled Development Limited Wednesday 19 November 2003 | joined the Board of Starpharma in August of this year to replace retiring Chairman Richard Oliver, who was the inaugural Chairman of this Company. Richard Oliver joined Starph
Slide 2: DNT and Share Placement
@ starpharma DNT A little over two years ago Starpharma made the strategic decision to join with the US pioneer of dendrimers, Dr Donald Tomalia, in establishing a new company to develop complementary applications of dendrimer nanotechnology. The company, Dendritic Nanotechnologies Inc, or ‘DNT’, wa
Slide 3: Board Remuneration and Corporate Governance
@ starpharma situation where this was a necessary part of a corporate restructure in the best interests of Starpharma shareholders. This item is not on the agenda today, and would require approval at a future general meeting of shareholders. Board Remuneration/cash burn Starpharma is not a high cost
Slide 4: Slide 4
Slide 5: Acknowledgement of contribution of Starpharma's Founding Chairman
Acknowledgement of contribution of Starpharma’s Founding Chairman a starpharma
Slide 6: Starpharma's Profile
Starpharma’s Profile 3 & starpharma
Slide 7: Starpharma's Profile (cont'd)
Starpharma’s Profile (cont’a) 4 2 starp Lerma
Slide 8: Starpharma's Profile (cont'd)
Starpharma’s Profile (cont'd) starpharma
Slide 9: Polyvalence & Dendrimers as Drugs
Polyvalence & Dendrimers as Drugs 6 oe starpharma
Slide 10: First Commercial Licence of Polyvalence
First Commercial Licence of Polyvalence starpharma
Slide 11: Starpharma Development Projects
Starpharma Development Projects a starpharma
Slide 12: HIV Prevention – An Unmet Medical Need for Women
HIV Prevention — An Unmet Medical Need for Women ~ HIV/AIDS is the number one priority disease of the US Government. - US$15 billion allocated over five years for the prevention and tre 63 starpharma
Slide 13: An Unmet Medical Need
— An Unmet Medical Need The market for an effective HIV preventative in Western countries is over.US$2 billion per annum starphar a
Slide 14: VivaGel: the first dendrimer-based drug to enter clinical trials
VivaGel™: the first dendrimer-based drug to enter clinical trials under the US regulatory system starpharma
Slide 15: VivaGel Protection in Macaques
VivaGel™ Pr in Macaques 2 re] starpharma
Slide 16: VivaGel Clinical Trial Strategy
VivaGel™ Clinical Trial Strategy 13 ee starpharma
Slide 17: Respiratory
Respiratory 1a a starp Lerma
Slide 18: Oncology
Oncology 15 @ starpharma
Slide 19: Biodefense
Biodefense 16 & starpharma
Slide 20: Starpharma Finances
Starpharma Finances
Slide 21: Current Grant Applications
Current Grant Applications 18 oe starpharma
Slide 22: Starpharma PDL – US Investment
Starpharma PDL — US Investment 19 ee starpharma
Slide 23: DNT – Key Assets and Relationships
DNT — Key Assets and Relationships SIGMA-ALDRICH FINE CHEMICALS
Slide 24: DNT – Key Achievements
DNT — Key Achievements 1 — a) starpharma
Slide 25: DNT – Products
DNT - Products 22 ee starpharma
Slide 26: Starpharma – The Year Ahead
Starpharma — The Year Ahead 0 ae) starpharma
Starpharma Holdings — Shareholder Meeting (November 2003) on 6ix